Pemtumomab

From Self-sufficiency
Revision as of 17:44, 14 July 2010 by Citation bot 1 (Talk) (Citations: [Pu173] added: first4, first5, first6, first7. Tweaked: first2, first3. You can use this bot yourself! Report bugs here.)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Pemtumomab
Monoclonal antibody
Type ?
Source Template:Infobox drug/mab source
Target MUC1
Clinical data
Routes of
administration		 Intraperitoneal
Identifiers
ATC code none
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]

It has been granted orphan drug status in Europe.[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
"-govo-" (ovarian tumor)
"-limo-" (immune system)
"-tumo-" (miscellaneous tumor)
"-leso-" (infectious lesions)
"-ciro-" (cardiovascular)
"-pro-" (prostate tumor)
"-baco-" (bacterial)
"-colo-" (colonic tumor)
§Withdrawn


40x30px This monoclonal antibody-related article is a stub. You can help ssf by expanding it.
  1. ↑ Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International journal of cancer. Journal international du cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524. 
  2. ↑ ClinicalTrials.gov
  3. ↑ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Pemtumomab&oldid=23105"